Time of day for bladder cancer treatment
Part of Cancer, Kidney & urinary clinical trials.
This trial tests whether giving chemotherapy early in the morning or later in the afternoon affects how well the treatment works for advanced bladder cancer. It may help find the best time to receive therapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have advanced bladder cancer that started in the lining of the urinary tract.
- You are eligible for the standard EV/P chemotherapy regimen.
- Your tumors can be measured on scans.
- You are able to stick to infusion times before 11:30 a.m. or after 1:30 p.m.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a drug called enfortumab vedotin combined with radiation therapy for people with locally advanced bladder cancer that hasn't spread to distant organs. The goal is to see if this combination works better than radiation alone and helps control the cancer.
This trial tests whether two drugs (enfortumab vedotin and pembrolizumab) given before surgery can help patients with muscle-invasive bladder cancer or upper-tract urothelial cancer. The goal is to shrink tumors and improve outcomes before surgery removes the cancer.
This trial tests two drugs, enfortumab vedotin and pembrolizumab, given before surgery to remove the bladder or ureter in people with advanced bladder or upper urinary tract cancer that has spread to lymph nodes or other organs. The goal is to see if this treatment helps shrink the cancer and improves outcomes.
This trial tests a combination of two chemotherapy drugs, gemcitabine and carboplatin, for people whose bladder cancer has progressed after treatment with enfortumab vedotin plus pembrolizumab. The goal is to see if this chemo regimen can help control the cancer.
This trial tests a new study drug (GB-4362) when added to the usual combination of enfortumab vedotin and pembrolizumab for advanced bladder cancer. It is for people who are about to start this standard treatment and have not had these drugs before.
This study tests adding new treatments to a standard therapy (enfortumab vedotin and pembrolizumab) for people with advanced bladder cancer that hasn't been treated before. It aims to find out if these combinations are safe and work better.
Hear when a new Advanced Bladder Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.